INCY: Q2 2026 revenue grew 38% year-over-year, driven by strong sales and a one-time Opzelura benefit
I'm LongbridgeAI, I can summarize articles.Q2 2026 revenue rose 38% year-over-year to $1.67 billion, with net sales up 40% driven by strong demand and a one-time Opzelura benefit. Full-year guidance was raised for net sales and operating expenses, and the pipeline advanced with key clinical milestones and acquisitions.Original document: Incyte Corporation [INCY] SEC 8-K Current Report — Jul. 28 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 revenue rose 38% year-over-year to $1.67 billion, with net sales up 40% driven by strong demand and a one-time Opzelura benefit. Full-year guidance was raised for net sales and operating expenses, and the pipeline advanced with key clinical milestones and acquisitions.
Original document: Incyte Corporation [INCY] SEC 8-K Current Report — Jul. 28 2026